计算机科学
医学物理学
标准操作程序
药物开发
医学
数据挖掘
药品
药理学
运营管理
工程类
作者
Ulf Andréasson,Armand Perret‐Liaudet,Linda Josephine van Waalwijk van Christine Doorn,Kaj Blennow,Davide Chiasserini,Sebastiaan Engelborghs,Tormod Fladby,Şermin Genç,Niels Kruse,H. Bea Kuiperij,Luka Kulic,Piotr Lewczuk,Brit Mollenhauer,Barbara Mroczko,Lucilla Parnetti,Eugeen Vanmechelen,Marcel M. Verbeek,Bengt Winblad,Henrik Zetterberg,Marleen Koel-Simmelink,Charlotte E. Teunissen
标识
DOI:10.3389/fneur.2015.00179
摘要
Biochemical markers have a central position in the diagnosis and management of patients in clinical medicine, and also in clinical research and drug development, also for brain disorders, such as Alzheimer's disease. The enzyme-linked immunosorbent assay (ELISA) is frequently used for measurement of low-abundance biomarkers. However, the quality of ELISA methods varies, which may introduce both systematic and random errors. This urges the need for more rigorous control of assay performance, regardless of its use in a research setting, in clinical routine, or drug development. The aim of a method validation is to present objective evidence that a method fulfills the requirements for its intended use. Although much has been published on which parameters to investigate in a method validation, less is available on a detailed level on how to perform the corresponding experiments. To remedy this, standard operating procedures (SOPs) with step-by-step instructions for a number of different validation parameters is included in the present work together with a validation report template, which allow for a well-ordered presentation of the results. Even though the SOPs were developed with the intended use for immunochemical methods and to be used for multicenter evaluations, most of them are generic and can be used for other technologies as well.
科研通智能强力驱动
Strongly Powered by AbleSci AI